TCM
SAGE

TimesSquare Capital Management’s Sage Therapeutics SAGE Stock Holding History

TimesSquare Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-550,075
Closed -$39.7M – 237
2019
Q4 		$39.7M Sell
550,075
-20,425
-4% -$2.51M 0.35% 125
2019
Q3 		$80M Buy
570,500
+61,500
+12% +$10.3M 0.71% 39
2019
Q2 		$93.2M Buy
509,000
+13,800
+3% +$2.35M 0.72% 38
2019
Q1 		$78.8M Buy
+495,200
New +$71.7M 0.61% 58

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TimesSquare Capital Management's SAGE Position: Q1 2020 in Review

TimesSquare Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 550,075 shares — an estimated $39.7M sold.

TimesSquare Capital Management first reported a position in SAGE in Q1 2019 and held it in 4 quarters. The position peaked at $93.2M in Q2 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • TimesSquare Capital Management reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • TimesSquare Capital Management sold 550,075 Sage Therapeutics shares in Q1 2020, an estimated $39.7M.
  • TimesSquare Capital Management first reported a position in Sage Therapeutics in Q1 2019 and held it in 4 quarters.
  • TimesSquare Capital Management's Sage Therapeutics position peaked at $93.2M in Q2 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on TimesSquare Capital Management's 13F filing for Q1 2020, filed 8 May 2020.